Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.63 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.39 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | HTR2B | P41595 | 6/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931707 | 1.00 | PRCP (0.63) | PRCPCHRNB2CHRNA4HTR2AHTR2C | |
| SCHEMBL9600234 | 0.89 | PRCP (0.57) | PRCPCHRNB2CHRNA4HTR2CKMT2A | |
| SCHEMBL31374588 | 0.89 | PRCP (0.57) | PRCPCHRNB2CHRNA4HTR2CKMT2A | |
| SCHEMBL31374586 | 0.89 | PRCP (0.57) | PRCPCHRNB2CHRNA4HTR2CKMT2A | |
| SCHEMBL3865487 | 0.79 | PRCP (0.97) | PRCP | |
| SCHEMBL28083503 | 0.79 | PRCP (0.90) | PRCP | |
| SCHEMBL1011373 | 0.77 | PRCP (1.00) | PRCP | |
| SCHEMBL29768302 | 0.77 | PRCP (1.00) | PRCP | |
| SCHEMBL2795999 | 0.77 | PRCP (1.00) | PRCP | |
| SCHEMBL2793867 | 0.77 | PRCP (1.00) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-108863905-B | Preparation method of indeno succinimide compound | 武汉理工大学 | 2022-03-18 | — | — | CN | disclosed |
| EP-2221296-B1 | FUSED INDANE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-8211907-B2 | Fused indane compound | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20100267695-A1 | FUSED INDANE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2221296-A1 | FUSED INDANE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-4118497-A | Antidepressantly active 5-(4-aminophenyl)-hexahydro-1H-indeno-(1,2-b)pyridine | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267695-A1 | FUSED INDANE COMPOUND | GRIN2A, GRIN2C, GRIN1 | PRCP 4180/4885CHRNB2 129/4885CHRNA4 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.